Evidence Summary
Evidence Level: Preliminary
Mechanism: Enrollment: Estimated, Sponsor Type: Other, Unknown / General
Safety: Cholinergic side effects (GI cramping, diarrhea, salivation, sweating, bradycardia). Avoid in asthma, mechanical obstruction. Overdose risk cholinergic crisis.
Dosing: 30–60 mg TID (sometimes 30 mg); titrate; study durations often 4–8 weeks for hemodynamic assessment.
Crossover RCT + review supports hemodynamic benefit, esp hyperadrenergic POTS. 30-60mg TID. Cholinergic SE dose-limiting. Reasonable targeted option.